NOVO · Novo Integrated Sciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.15M | $3.17M | $3.89M | $3.29M | $2.56M | $3.42M | $13.85M | $2.87M | $3.16M | $2.38M |
| Cost of Revenue | $2.25M | $1.85M | $1.95M | $1.98M | $1.59M | $1.68M | $11.44M | $1.65M | $1.90M | $1.10M |
| Gross Profit | $896.9K | $1.32M | $1.94M | $1.31M | $970.9K | $1.74M | $2.41M | $1.22M | $1.27M | $1.28M |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $3.41M | $2.86M | $5.25M | $2.74M | $2.76M | $3.97M | $3.60M | $3.31M | $2.63M | $1.68M |
| Total Operating Expenses | $3.42M | $2.86M | $5.26M | $2.74M | $2.76M | $3.98M | $3.61M | $3.34M | $2.63M | $1.68M |
| D&A | $556.7K | $568.2K | $572.4K | $579.6K | $552.6K | $586.2K | $881.6K | $773.6K | $694.3K | $13.9K |
| Operating Income | ($2.52M) | ($1.54M) | ($3.32M) | ($1.43M) | ($1.79M) | ($2.24M) | ($1.20M) | ($2.12M) | ($1.36M) | ($402.0K) |
| Interest Expense | $178.4K | $138.7K | $143.4K | $9.6K | $123.9K | $167.2K | $513.4K | $1.23M | $68.7K | $48.2K |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($13.74M) | ($2.75M) | ($4.68M) | ($1.50M) | ($4.62M) | ($3.94M) | ($3.81M) | ($4.81M) | ($1.81M) | ($411.2K) |
| EPS - Basic | ($0.74) | ($0.16) | ($0.28) | ($0.01) | ($0.17) | ($0.07) | ($0.02) | - | - | - |
| EPS - Diluted | ($0.10) | ($0.16) | ($0.28) | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $844.6K | $651.7K | $1.64M | $416.3K | $609.7K | $878.7K | $2.18M | $15.94M | $8.80M | $8.29M |
| Accounts Receivable | $1.92M | $2.15M | $2.64M | $1.47M | $923.6K | $960.1K | $1.02M | $1.25M | $1.70M | $1.47M |
| Inventory | $1.00M | $947.4K | $1.27M | $1.11M | $925.1K | $1.01M | $879.0K | $334.4K | $364.1K | $339.4K |
| Accounts Payable | $3.24M | $2.17M | $3.40M | $3.51M | $2.04M | $2.08M | $1.80M | $1.11M | $1.31M | $1.45M |
| Current Assets | $5.41M | $5.02M | $6.81M | $4.39M | $4.05M | $4.46M | $5.73M | $19.02M | $12.24M | $11.13M |
| Total Assets | $32.14M | $34.95M | $37.24M | $35.56M | $36.49M | $37.75M | $40.87M | $70.32M | $63.93M | $61.96M |
| Current Liabilities | $14.58M | $9.96M | $10.92M | $7.90M | $6.18M | $12.57M | $14.07M | $11.55M | $15.65M | $8.46M |
| Long-term Debt | $157.7K | $157.5K | $157.3K | $342.4K | $157.0K | $157.9K | $161.5K | $5.43M | $9.85M | $9.62M |
| Total Liabilities | $17.53M | $13.06M | $13.96M | $11.06M | $9.53M | $17.06M | $18.83M | $25.81M | $20.27M | $18.15M |
| Stockholders' Equity | $14.89M | $22.19M | $23.58M | $24.82M | $27.25M | $20.95M | $22.31M | $44.55M | $43.64M | $43.86M |
| Retained Earnings | ($83.20M) | ($74.46M) | ($71.71M) | ($67.03M) | ($62.38M) | ($57.75M) | ($53.82M) | ($27.58M) | ($22.78M) | ($20.97M) |
Cash Flow
| Line item | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($2.15M) | - | - | ($278.2K) | - | - | ($759.1K) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | ($91.1K) | - |
| Financing Cash Flow | - | - | $3.30M | - | - | ($1.03M) | - | - | $1.40M | - |
| CapEx | - | - | - | - | - | - | $200.8K | $618 | $120.4K | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($879.5K) | - |
Ratios
| Metric | Q3 '24 | Q2 '24 | Q1 '24 | Q3 '23 | Q2 '23 | Q1 '23 | Q3 '22 | Q2 '22 | Q1 '22 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 28.5% | 41.8% | 50.0% | 39.9% | 38.0% | 50.9% | 17.4% | 42.4% | 40.1% | 53.8% |
| Operating margin | -80.0% | -48.6% | -85.3% | -43.4% | -69.9% | -65.6% | -8.7% | -73.9% | -43.1% | -16.9% |
| EBITDA margin | -62.3% | -30.6% | -70.5% | -25.8% | -48.3% | -48.4% | -2.3% | -47.0% | -21.2% | -16.3% |
| Net margin | -436.0% | -86.6% | -120.3% | -45.5% | -180.8% | -115.1% | -27.5% | -167.5% | -57.1% | -17.3% |
| Free cash flow margin | - | - | - | - | - | - | - | - | -27.8% | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 0.49 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 108.3% | 90.2% | 135.0% | 83.3% | 107.8% | 116.2% | 26.0% | 115.4% | 83.2% | 70.6% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -42.8% | -7.9% | -12.6% | -4.2% | -12.7% | -10.4% | -9.3% | -6.8% | -2.8% | -0.7% |
| Return on equity | -92.3% | -12.4% | -19.8% | -6.0% | -17.0% | -18.8% | -17.1% | -10.8% | -4.1% | -0.9% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.37 | 0.50 | 0.62 | 0.56 | 0.66 | 0.35 | 0.41 | 1.65 | 0.78 | 1.32 |
| Quick ratio | 0.30 | 0.41 | 0.51 | 0.42 | 0.51 | 0.27 | 0.34 | 1.62 | 0.76 | 1.28 |
| Cash ratio | 0.06 | 0.07 | 0.15 | 0.05 | 0.10 | 0.07 | 0.15 | 1.38 | 0.56 | 0.98 |
| Leverage | ||||||||||
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.12 | 0.23 | 0.22 |
| Debt / Assets | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.08 | 0.15 | 0.16 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -14.1x | -11.1x | -23.1x | -149.5x | -14.4x | -13.4x | -2.3x | -1.7x | -19.8x | -8.3x |
| Equity multiplier | 2.16 | 1.58 | 1.58 | 1.43 | 1.34 | 1.80 | 1.83 | 1.58 | 1.46 | 1.41 |
| Liabilities / Assets | 0.55 | 0.37 | 0.37 | 0.31 | 0.26 | 0.45 | 0.46 | 0.37 | 0.32 | 0.29 |
| Efficiency | ||||||||||
| Asset turnover | 0.10 | 0.09 | 0.10 | 0.09 | 0.07 | 0.09 | 0.34 | 0.04 | 0.05 | 0.04 |
| Inventory turnover | 2.25 | 1.95 | 1.53 | 1.79 | 1.71 | 1.66 | 13.02 | 4.94 | 5.21 | 3.24 |
| Days sales outstanding | 222d | 248d | 247d | 163d | 132d | 102d | 27d | 159d | 196d | 225d |
| Days inventory outstanding | 162d | 187d | 238d | 204d | 213d | 219d | 28d | 74d | 70d | 113d |
| Days payable outstanding | 524d | 430d | 638d | 648d | 470d | 451d | 57d | 244d | 253d | 481d |
| Cash conversion cycle | -140d | 6d | -153d | -281d | -125d | -129d | -3d | -11d | 13d | -143d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -4.3% | 24.0% | 13.8% | -76.2% | -10.9% | 8.1% | 481.8% | 38.2% | 46.7% | 129.3% |
| Revenue CAGR (3y) | 9.8% | 15.2% | 21.8% | 46.9% | 1.7% | 10.3% | 77.2% | 9.2% | 11.9% | 0.8% |
| Revenue CAGR (5y) | 4.8% | 7.6% | 11.5% | 7.2% | 3.6% | 13.5% | 46.0% | - | - | - |
| Gross profit growth (YoY) | -31.7% | 36.4% | 11.8% | -45.4% | -20.2% | 37.4% | 88.1% | 61.9% | 56.1% | 167.7% |
| Operating income growth (YoY) | -76.2% | 13.8% | -48.0% | -18.9% | 15.7% | -64.4% | -199.2% | -59.9% | -80.0% | -411.7% |
| Net income growth (YoY) | -817.8% | 40.6% | -18.9% | 60.7% | 3.8% | -117.8% | -826.6% | -258.6% | -134.2% | -318.3% |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -40.0% | -18.6% | 12.6% | 11.3% | -38.8% | -52.0% | -49.1% | 52.6% | 49.5% | 48.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-08-31.
Business segments
$13.29M totalHealth Care Services$8.30M · 62.4%
Product Sales$4.92M · 37.0%
Corporate$78.3K · 0.6%
Peer comparison
Same SIC group: Engines & Turbines
Comparing Novo Integrated Sciences against the 5 most active filers in the same SIC group.